Compounds of formula (I)
wherein A is N or N
+
—O
−
; n is 0, 1, or 2; Y is O, S, —NH—, and —N-alkyl-; Ar
1
is both 6-membered aromatic rings; Ar
2
is 5- or 6-membered aromatic rings with a —NR
8
R
9
group, as defined herein. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.
Compounds of formula (I)
wherein n is 0, 1, or 2; A is N or N
+
—O
−
; X is O, S, —NH—, and —N-alkyl-; Ar
1
is a 6-membered aromatic ring; and Ar
2
is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.
Compounds of formula (I)
wherein A is N or N
+
—O
−
; n is 0, 1, or 2; Y is O, S, —NH—, and —N-alkyl-; Ar
1
is both 6-membered aromatic rings; Ar
2
is 5- or 6-membered aromatic rings with a —NR
8
R
9
group, as defined herein. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.
Fused bicycloheterocycle substituted quinuclidine derivatives as .alpha.7 nAChR modulators
申请人:Abbott Laboratories
公开号:EP2308875A1
公开(公告)日:2011-04-13
Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N+-O-; X is O, S, -NH-, and -N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by a7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.